(Sharecast News) - Uniphar reported a strong performance for the first half of 2025 on Tuesday, achieving double-digit adjusted earnings per share growth, surpassing its own expectations.
The AIM-traded company experienced around 8% organic gross profit growth, supported by lower finance costs.

It said its pharmaceutical division, Uniphar Pharma, delivered...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE